Zobrazeno 1 - 10
of 28
pro vyhledávání: '"April M. Barbour"'
Autor:
Susan Petusky, Brad Yuska, Zhinyin Xun, Gongfu Zhou, Nithya Srinivas, April M. Barbour, Thomas Marbury, Naresh Punwani, Xuejun Chen, Noam Epstein, Swamy Yeleswaram
Publikováno v:
Journal of Clinical Pharmacology
Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft‐versus‐host disease. The objective of this study was to assess pharmacokinetics and safety of 300‐mg itacitinib dosed in participants with normal r
Autor:
Robert Zeiser, Gérard Socié, Mark A Schroeder, Sunil Abhyankar, Carlos Pinho Vaz, Mi Kwon, Johannes Clausen, Leonid Volodin, Sebastian Giebel, Manuel Jurado Chacon, Gabrielle Meyers, Monalisa Ghosh, Dries Deeren, Jaime Sanz, Rodica Morariu-Zamfir, Michael Arbushites, Mani Lakshminarayanan, April M Barbour, Yi-Bin Chen
Publikováno v:
LANCET HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Background Acute graft-versus-host disease (GVHD) is a common and life-threatening complication of allogeneic haematopoietic stem cell transplantation (HSCT); there is an urgent unmet need for effective therapies. We aimed to evaluate the Janus kinas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353d31983440702d66df5561eef6119c
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15756
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15756
Autor:
Naresh Punwani, Evan Cimino, Swamy Yeleswaram, Noam Epstein, Phillip Wang, Robert R. Landman, Xuejun Chen, Brad Yuska, Kevin He, April M. Barbour
Publikováno v:
The Journal of Clinical Pharmacology. 59:1641-1647
Itacitinib is a potent, selective JAK-1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft-versus-host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily eliminated via metabolism by cytoc
Autor:
Noam Epstein, Evan Cimino, Swamy Yeleswaram, Xuejun Chen, April M. Barbour, Gongfu Zhou, Kevin Rockich, Caterina Leonetti‐Whalen, Naresh Punwani
Publikováno v:
Journal of clinical pharmacologyReferences. 61(7)
Itacitinib is a potent, selective JAK-1 inhibitor currently in development for the treatment of chronic graft-vs-host-disease in combination with corticosteroids. Itacitinib is primarily eliminated via cytochrome P450 3A metabolism with minimal renal
Autor:
William L. Marshall, Luzelena Caro, Jocelyn Gilmartin, Dennis Wolford, Zifang Guo, April M. Barbour, Monika Martinho, Christina Reitmann, Lynn Webster, Pavan Vaddady, Deborah Panebianco, Iain Fraser, Wendy W. Yeh, Marian Iwamoto, Fang Liu, Patricia Jumes, Robert Valesky, Joan R. Butterton, Hwa-Ping Feng
Publikováno v:
Clinical and Translational Science. 11:562-572
The aims of these phase I trials were to evaluate the pharmacokinetic interaction between elbasvir (EBR) or grazoprevir (GZR) and buprenorphine/naloxone (BUP/NAL). Trial 1 was a single-dose trial in healthy participants. Trial 2 was a multiple-dose t
Autor:
Michael F. Crutchlow, Linda Morrow, Michael C. Marcos, Kate Mostoller, Chantal Mahon, April M. Barbour, Elaine Watkins, John Palcza, Yang Xu, Marcus Hompesch
Publikováno v:
Diabetes, Obesity and Metabolism. 20:400-408
Aims MK-1293 is an insulin glargine that has an identical amino acid sequence to that of Lantus, the originator insulin glargine. Two euglycemic clamp studies, one in subjects with Type 1 diabetes (T1D) and one in healthy subjects, were conducted to
Autor:
April M. Barbour, Michael J. Fossler
Publikováno v:
The Journal of Clinical Pharmacology. 58:25-28
Autor:
Swamy Yeleswaram, Hongqi Xue, Naresh Punwani, April M. Barbour, Xuejun Chen, Xiaohua Gong, Robert Landman, Noam Epstein, Borje Darpo, Kevin He
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(6)
Itacitinib is a JAK1-selective inhibitor in phase 3 development in graft-versus-host disease. A post hoc electrocardiogram (ECG) analysis and a plasma concentration-QTc (C-QTc) analysis were performed to assess cardiac safety using data from the firs
Autor:
Thomas F Haws, Robert J. Gropler, John J. Lepore, Michael J. Fossler, Laura Demopoulos, Victor G. Davila-Roman, Eric Olson, Zixing Fang, April M. Barbour, Stuart D. Russell
Publikováno v:
JACC: Heart Failure. 4:559-566
Objectives This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure. Background Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes. Methods We perfor
Publikováno v:
The AAPS Journal. 16:749-755
Pediatric dosing recommendations are often not based on allometry, despite recognition that metabolic processes in mammals scale to the ¾ power. This report reviews the allometric size model for clearance and its implications for defining doses for